CSL (CSL) Stock Overview
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
CSL Community Fair Values
Create NarrativeSee what 319 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
CSL Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$145.00 |
| 52 Week High | AU$275.79 |
| 52 Week Low | AU$147.18 |
| Beta | 0.28 |
| 1 Month Change | -19.27% |
| 3 Month Change | -20.72% |
| 1 Year Change | -44.76% |
| 3 Year Change | -51.06% |
| 5 Year Change | -46.24% |
| Change since IPO | 18,025.18% |
Recent News & Updates
My view on CSL Limited is positive. It’s a high-quality growth stock with strong barriers to entry through its global plasma network.
One stock I find particularly compelling is CSL Limited (ASX: CSL), primarily due to its strong competitive positioning, structural growth drivers, and valuation complexity. From a fundamental perspective, CSL operates in the global plasma therapies and specialty pharmaceuticals market, where demand is relatively inelastic and supported by long-term healthcare trends.CSL's (ASX:CSL) Soft Earnings Are Actually Better Than They Appear
Feb 17
Recent updates
My view on CSL Limited is positive. It’s a high-quality growth stock with strong barriers to entry through its global plasma network.
One stock I find particularly compelling is CSL Limited (ASX: CSL), primarily due to its strong competitive positioning, structural growth drivers, and valuation complexity. From a fundamental perspective, CSL operates in the global plasma therapies and specialty pharmaceuticals market, where demand is relatively inelastic and supported by long-term healthcare trends.CSL's (ASX:CSL) Soft Earnings Are Actually Better Than They Appear
Feb 17
Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook
Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases. What are the underlying business or industry changes driving this perspective?CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up
Sep 25Is CSL Limited (ASX:CSL) Trading At A 43% Discount?
Aug 07Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly
Jun 14Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog
Apr 16
CSL is undervalued in High Tax Scenario
CSL Behring: This is CSL's largest segment and the global leader (#1) in plasma therapies within an estimated US$30 billion industry.11 It focuses on researching, developing, manufacturing, and distri
Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position
Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings.Shareholder Returns
| CSL | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -4.3% | -2.5% | 1.0% |
| 1Y | -44.8% | -43.1% | 7.7% |
Return vs Industry: CSL underperformed the Australian Biotechs industry which returned -43.1% over the past year.
Return vs Market: CSL underperformed the Australian Market which returned 7.7% over the past year.
Price Volatility
| CSL volatility | |
|---|---|
| CSL Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: CSL has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CSL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1916 | 29,904 | Gordon Naylor | www.csl.com |
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants.
CSL Limited Fundamentals Summary
| CSL fundamental statistics | |
|---|---|
| Market cap | AU$70.98b |
| Earnings (TTM) | AU$1.98b |
| Revenue (TTM) | AU$21.84b |
Is CSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSL income statement (TTM) | |
|---|---|
| Revenue | US$15.41b |
| Cost of Revenue | US$7.42b |
| Gross Profit | US$7.99b |
| Other Expenses | US$6.60b |
| Earnings | US$1.40b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 18, 2026
| Earnings per share (EPS) | 2.90 |
| Gross Margin | 51.87% |
| Net Profit Margin | 9.06% |
| Debt/Equity Ratio | 46.7% |
How did CSL perform over the long term?
See historical performance and comparisonDividends
Does CSL pay a reliable dividends?
See CSL dividend history and benchmarks| CSL dividend dates | |
|---|---|
| Ex Dividend Date | Mar 10 2026 |
| Dividend Pay Date | Apr 09 2026 |
| Days until Ex dividend | 13 days |
| Days until Dividend pay date | 43 days |
Does CSL pay a reliable dividends?
See CSL dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/24 13:32 |
| End of Day Share Price | 2026/02/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CSL Limited is covered by 26 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Lyanne Harrison | BofA Global Research |